These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36618081)

  • 41. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.
    Nguyen TP; Do Q; Phan LT; Dinh DV; Khong H; Hoang LV; Nguyen TV; Pham HN; Chu MV; Nguyen TT; Pham QD; Le TM; Trang TNT; Dinh TT; Vo TV; Vu TT; Nguyen QBP; Phan VT; Nguyen LV; Nguyen GT; Tran PM; Nghiem TD; Tran TV; Nguyen TG; Tran TQ; Nguyen LT; Do AT; Nguyen DD; Ho SA; Nguyen VT; Pham DT; Tran HB; Vu ST; Hoang SX; Do TM; Nguyen XT; Le GQ; Tran T; Cao TM; Dao HM; Nguyen TTT; Doan UY; Le VTT; Tran LP; Nguyen NM; Nguyen NT; Pham HTT; Nguyen QH; Nguyen HT; Nguyen HLK; Tran VT; Tran MTN; Nguyen TTT; Ha PT; Huynh HT; Nguyen KD; Thuan UT; Doan CC; Do SM
    Lancet Reg Health West Pac; 2022 Jul; 24():100474. PubMed ID: 35602004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Pérez-Rodríguez S; de la Caridad Rodríguez-González M; Ochoa-Azze R; Climent-Ruiz Y; Alberto González-Delgado C; Paredes-Moreno B; Valenzuela-Silva C; Rodríguez-Noda L; Perez-Nicado R; González-Mugica R; Martínez-Pérez M; Sánchez-Ramírez B; Hernández-García T; Díaz-Machado A; Tamayo-Rodríguez M; Martín-Trujillo A; Rubino-Moreno J; Suárez-Batista A; Dubed-Echevarría M; Teresa Pérez-Guevara M; Amoroto-Roig M; Chappi-Estévez Y; Bergado-Báez G; Pi-Estopiñán F; Chen GW; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V
    Vaccine; 2022 Mar; 40(13):2068-2075. PubMed ID: 35164986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
    Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
    Hui AM; Li J; Zhu L; Tang R; Ye H; Lin M; Ge L; Wang X; Peng F; Wu Z; Guo X; Shi Y; Pan H; Zhu J; Song Z; Qiu J; Wang W; Zheng J; Ozhelvaci O; Shpyro S; Bushway M; Derhovanessian E; Kühnle MC; Luxemburger U; Muik A; Shishkova Y; Khondker Z; Hu S; Lagkadinou E; Şahin U; Türeci Ö; Zhu F
    Lancet Reg Health West Pac; 2022 Dec; 29():100586. PubMed ID: 36120090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
    Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
    Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.
    Wang XY; Mahmood SF; Jin F; Cheah WK; Ahmad M; Sohail MA; Ahmad W; Suppan VK; Sayeed MA; Luxmi S; Teo AH; Lee LY; Qi YY; Pei RJ; Deng W; Xu ZH; Yang JM; Zhang Y; Guan WX; Yu X
    Emerg Microbes Infect; 2022 Dec; 11(1):1910-1919. PubMed ID: 35686572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
    Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
    Evans TG; Bussey L; Eagling-Vose E; Rutkowski K; Ellis C; Argent C; Griffin P; Kim J; Thackwray S; Shakib S; Doughty J; Gillies J; Wu J; Druce J; Pryor M; Gilbert S
    Lancet Infect Dis; 2022 Jun; 22(6):857-866. PubMed ID: 35305317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.